News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Reports Third Quarter Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and nine months ended September 30, 2006. The net loss for the third quarter of 2006 was $6.8 million, or $0.13 per share, compared with a net loss for the third quarter
View HTML
Toggle Summary AVI BioPharma to Present Strategic Overview at Two Investor Conferences
Presentations to Take Place at Rodman & Renshaw 8th Annual Global Healthcare Conference and Paulson Investment's 29th Annual Westergaard SmallCap Conference PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 6, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), President and COO Alan P.
View HTML
Toggle Summary AVI BioPharma Announces 2006 Third Quarter Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 1, 2006--AVI BioPharma Inc. (Nasdaq: AVII) today announced that the company will release its 2006 third quarter financial results prior to market open on Wednesday, November 8. Due to travel schedules, management will hold a conference call on Wednesday,
View HTML
Toggle Summary AVI BioPharma Discusses Phase II Cardiovascular Clinical Study
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 31, 2006--Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI's partner Cook Group Inc. presented promising preliminary observations at the 18th Annual Transcatheter
View HTML
Toggle Summary AVI BioPharma Publishes Preclinical Data Showing NEUGENE Antisense Inhibition of Multiple Strains of Influenza A Virus
Business Editors/Biotech Writers PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced publication of preclinical results from studies carried out by an international team of researchers showing the ability of NEUGENE(R) antisense to inhibit multiple
View HTML
Toggle Summary AVI BioPharma Presents Successful Trial Results Using NEUGENE Antisense to Alter Drug Metabolism in Humans
Business Editors/Biotech Writers PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 19, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented data and analysis from four NEUGENE(R) antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in
View HTML
Toggle Summary AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 18, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced the initiation of a clinical program to assess the safety and effectiveness of AVI-5126, a new generation of NEUGENE(R) antisense drug for treating coronary vascular disease.
View HTML
Toggle Summary AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 4, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety,
View HTML
Toggle Summary AVI BioPharma Presents Positive Preclinical Data Evaluating NEUGENE Antisense Compounds Against Influenza A Virus and the E. coli Bacteria
Business Editors/Biotech Writers BIOWIRE2K ICAAC 2006 PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 29, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE(R) antisense technology against influenza A and E. coli infection.
View HTML
Toggle Summary AVI BioPharma to Present at UBS Global Life Sciences Conference
PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Wednesday, Sept. 27, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Life Sciences Conference to be held at
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.